|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008838,
umls-concept:C0038952,
umls-concept:C0144576,
umls-concept:C0242656,
umls-concept:C0282461,
umls-concept:C0348016,
umls-concept:C0439849,
umls-concept:C0441771,
umls-concept:C0442120,
umls-concept:C0677886,
umls-concept:C1333355,
umls-concept:C1512288,
umls-concept:C1882417
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
2008-7-21
|
|
pubmed:abstractText |
We hypothesized that common polymorphisms in excision repair cross-complementation group 1 (ERCC1), involved in nucleotide excision repair of platinum-induced damage, would be associated with progression-free survival (PFS) and overall survival (OS) in women with optimally resected, stage III epithelial ovarian cancer (EOC) treated with cisplatin and paclitaxel (C+P).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3598-606
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18640939-Aged,
pubmed-meshheading:18640939-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18640939-Cisplatin,
pubmed-meshheading:18640939-DNA-Binding Proteins,
pubmed-meshheading:18640939-Disease Progression,
pubmed-meshheading:18640939-Disease-Free Survival,
pubmed-meshheading:18640939-Drug Resistance, Neoplasm,
pubmed-meshheading:18640939-Endonucleases,
pubmed-meshheading:18640939-Female,
pubmed-meshheading:18640939-Humans,
pubmed-meshheading:18640939-Infusions, Intravenous,
pubmed-meshheading:18640939-Infusions, Parenteral,
pubmed-meshheading:18640939-Kaplan-Meier Estimate,
pubmed-meshheading:18640939-Middle Aged,
pubmed-meshheading:18640939-Neoplasm Staging,
pubmed-meshheading:18640939-Neoplasms, Glandular and Epithelial,
pubmed-meshheading:18640939-Ovarian Neoplasms,
pubmed-meshheading:18640939-Paclitaxel,
pubmed-meshheading:18640939-Polymorphism, Single Nucleotide
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
|
|
pubmed:affiliation |
University of Pittsburgh Magee-Women's Hospital; Precision Therapeutics/PTI, Pittsburgh, PA 15213, USA. tkrivak@mail.magee.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III,
Research Support, N.I.H., Extramural
|
